Jiangxi Fushine Pharmaceutical Hits Day High with 5.32% Surge

Jiangxi Fushine Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 5.32% on July 1, 2026. The stock reached an intraday high of CNY 23.81, showcasing its strong market activity. Over the past week, Jiangxi Fushine has outperformed the China Shanghai Composite, which recorded a mere 0.04% increase, with a weekly gain of 5.37%. In the broader context, the company has demonstrated impressive growth metrics, with a remarkable 51.66% increase over the past month and a substantial 155.08% rise over the past year, significantly surpassing the China Shanghai Composite's 18.93% performance during the same period. Year-to-date, Jiangxi Fushine has achieved a 54.47% gain, further solidifying its position in the pharmaceuticals and biotechnology sector. Despite some long-term fundamental weaknesses, including a low average Return on Capital Employed (ROCE) of 4.17%, the company has reported a notable net profit growth of 692.07% in its recent quarterly results. This performance highlights Jiangxi Fushine's ability to navigate market conditions effectively, making it a noteworthy player in its industry.